Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 P276-00 monotherapy in cyclin D1-positive advanced malignant melanoma
ACTRN12609000815268Phase 2Completed
- Sponsor
- Piramal Enterprises Limited
- Start
- Sep 2009
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of P276 in melanoma, sponsored by Piramal Enterprises Limited. Primary endpoint: Progression-free survival rate at Day 168. Started Sep 2009; status: completed.
02
Drugs
P276
03
Conditions
melanoma
Beyond the preview
Go deeper on ACTRN12609000815268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609000815268.